https://stockwhiz.ai/news/veradermics-to-hold-conference-call-to-discuss-12-month-long-term-resu-d0e8c6e6Stockwhizen2026-11-08T23:00:00.092ZVeradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Losshttps://stockwhiz.ai/news/onterris-acquires-ecoz-environmental-consultants-strategically-expandi-24c52788Stockwhizen2026-11-08T22:01:00.094ZOnterris Acquires EcOz Environmental Consultants, Strategically Expanding Consultancy Services in Northern Australiahttps://stockwhiz.ai/news/vir-biotechnology-announces-expanded-phase-2-solstice-data-for-elebsir-34d37d00Stockwhizen2026-11-08T21:45:00.101ZVir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Datahttps://stockwhiz.ai/news/mineralys-therapeutics-presents-new-late-breaking-data-from-transform--a24d03a7Stockwhizen2026-11-08T21:35:00.150ZMineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026https://stockwhiz.ai/news/vir-biotechnology-announces-primary-endpoint-met-in-pivotal-phase-3-ec-b23881bfStockwhizen2026-11-08T21:15:00.100ZVir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Deltahttps://stockwhiz.ai/news/radnet-reports-third-quarter-financial-results-with-record-quarterly-r-3db41230Stockwhizen2026-11-08T21:01:00.383ZRadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Rangeshttps://stockwhiz.ai/news/cideb-sirna-normalizes-liver-fat-and-improves-liver-injury-markers-in--c8efc0e8Stockwhizen2026-11-08T21:00:00.137ZCIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLDhttps://stockwhiz.ai/news/avita-medical-to-host-investor-webinar-briefing-c26c8410Stockwhizen2026-11-08T20:30:00.103ZAVITA Medical to Host Investor Webinar Briefinghttps://stockwhiz.ai/news/statement-from-nvidia-board-of-directors-87d59fbbStockwhizen2026-11-08T20:00:00.108ZStatement from NVIDIA Board of Directorshttps://stockwhiz.ai/news/allergan-aesthetics-reports-improved-satisfaction-with-facial-appearan-de17a405Stockwhizen2026-11-08T17:45:00.032ZAllergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medicationshttps://stockwhiz.ai/news/johnson-johnson-reports-73-psa-response-rate-with-investigational-pasr-d79d425aStockwhizen2026-11-08T16:01:20.244ZJohnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancerhttps://stockwhiz.ai/news/velinotamig-a-bcmaxcd3-t-cell-engager-achieves-complete-renal-response-353a3d2dStockwhizen2026-11-08T15:30:00.131ZVelinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026https://stockwhiz.ai/news/crispr-therapeutics-provides-update-on-zugocabtagene-geleucel-zugo-cel-24b2f4fdStockwhizen2026-11-08T15:30:00.094ZCRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseaseshttps://stockwhiz.ai/news/cabaletta-bio-presents-new-rese-cel-phase-1-2-clinical-data-at-acr-con-cd0e3a07Stockwhizen2026-11-08T15:00:00.151ZCabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseaseshttps://stockwhiz.ai/news/club-offers-for-travel-enthusiasts-in-germany-86df3ecbStockwhizen2026-11-08T09:56:46.524ZClub Offers for Travel Enthusiasts in Germanyhttps://stockwhiz.ai/news/club-offers-for-travel-enthusiasts-in-canada-e32f5421Stockwhizen2026-11-08T08:14:42.962ZClub Offers for Travel Enthusiasts in Canadahttps://stockwhiz.ai/news/club-offers-for-travel-enthusiasts-in-the-u-s-15d7065bStockwhizen2026-11-08T05:00:00.222ZClub Offers for Travel Enthusiasts in the U.S.https://stockwhiz.ai/news/north-georgia-flooding-u-haul-offers-30-days-free-storage-at-14-stores-6e9124bbStockwhizen2026-11-08T00:28:00.091ZNorth Georgia Flooding: U-Haul Offers 30 Days Free Storage at 14 Storeshttps://stockwhiz.ai/news/club-offers-for-travel-enthusiasts-in-the-uk-4bd2d030Stockwhizen2026-11-08T00:01:00.050ZClub Offers for Travel Enthusiasts in the UKhttps://stockwhiz.ai/news/voyager-awarded-nasa-clps-2-contract-c8d87dd7Stockwhizen2026-11-07T23:00:00.081ZVoyager Awarded NASA CLPS 2 Contracthttps://stockwhiz.ai/news/firefly-aerospace-selected-as-a-vendor-for-nasa-s-10-billion-clps-2-in-d1cf915dStockwhizen2026-11-07T22:55:12.099ZFirefly Aerospace Selected as a Vendor for NASA’s $10 Billion CLPS 2 Initiativehttps://stockwhiz.ai/news/arrowhead-pharmaceuticals-presents-plozasiran-data-highlighting-sustai-490ccf06Stockwhizen2026-11-07T21:15:00.093ZArrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rateshttps://stockwhiz.ai/news/four-course-records-and-28-olympic-trials-qualifiers-highlight-histori-bd132cc6Stockwhizen2026-11-07T21:07:56.350ZFour Course Records and 28 Olympic Trials Qualifiers Highlight Historic 2026 CNO Financial Indianapolis Monumental Marathonhttps://stockwhiz.ai/news/diginex-announces-extension-of-long-stop-date-for-proposed-acquisition-74453c27Stockwhizen2026-11-07T19:07:00.105ZDiginex Announces Extension of Long Stop Date for Proposed Acquisition of Resulticks and Convenes Extraordinary General Meetinghttps://stockwhiz.ai/news/fusion-power-global-capital-branded-streaming-and-neurology-breakthrou-269fcbecStockwhizen2026-11-07T17:06:20.566ZFusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Televisionhttps://stockwhiz.ai/analyst-ratings/iren-limited-ccorf-buy-pt-79-b5f8b10eStockwhizen2026-11-07T15:58:50.810ZCCORF maintains Buy on IREN Limited, maintains PT at $79https://stockwhiz.ai/news/qumulusai-to-report-third-quarter-2026-financial-results-on-nov-10-202-ad767b2aStockwhizen2026-11-07T15:50:00.081ZQumulusAI to Report Third Quarter 2026 Financial Results on Nov. 10, 2026https://stockwhiz.ai/news/johnson-johnson-announces-icotyde-icotrokinra-delivers-significant-imp-bf8100e3Stockwhizen2026-11-07T15:03:00.228ZJohnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptidehttps://stockwhiz.ai/news/johnson-johnson-announces-new-phase-2-nipocalimab-study-data-in-sj-gre-f5839c5aStockwhizen2026-11-07T15:03:00.023ZJohnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patientshttps://stockwhiz.ai/news/new-real-world-evidence-presented-by-organon-at-the-american-college-o-47bbc271Stockwhizen2026-11-07T15:00:00.118ZNew Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare Systemhttps://stockwhiz.ai/news/agoda-names-five-quieter-corners-of-asia-to-catch-the-snow-this-season-df121cb5Stockwhizen2026-11-07T03:04:36.958ZAgoda names five quieter corners of Asia to catch the snow this seasonhttps://stockwhiz.ai/news/diversified-royalty-corp-announces-third-quarter-2026-results-7a0662d2Stockwhizen2026-11-07T00:49:33.245ZDiversified Royalty Corp. Announces Third Quarter 2026 Resultshttps://stockwhiz.ai/news/lifemd-reschedules-third-quarter-2026-earnings-release-and-conference--d121f59bStockwhizen2026-11-07T00:25:00.095ZLifeMD Reschedules Third Quarter 2026 Earnings Release and Conference Call to November 12, 2026https://stockwhiz.ai/news/spaccircle-acquisition-corp-announces-the-separate-trading-of-its-clas-d3d705d2Stockwhizen2026-11-07T00:23:37.085ZSPACCircle Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares, Warrants and Rights, Commencing November 10, 2026https://stockwhiz.ai/news/datavault-ai-founder-nathaniel-bradley-sues-board-fa8d24eaStockwhizen2026-11-07T00:04:26.391ZDatavault AI Founder Nathaniel Bradley Sues Boardhttps://stockwhiz.ai/news/james-hardie-industries-set-to-join-s-p-midcap-400-f5468bfdStockwhizen2026-11-06T23:10:19.520ZJames Hardie Industries Set to Join S&P MidCap 400https://stockwhiz.ai/news/biofrontera-inc-to-report-third-quarter-2026-financial-results-on-nove-e9dc8f02Stockwhizen2026-11-06T23:08:00.111ZBiofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026